DOCSLIB.ORG

Voting Report 2020

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Voting Report 2020 Exercising of Shareholder Rights – Information December 2020 As a result of the adoption of the “Popular Initiative against Fat-Cat Salaries” in 2014, pension funds have an obligation to exercise shareholder rights in the interests of the insured persons and to disclose how the pension funds voted. This regulation applies for public limited companies with registered office in Switzerland and whose shares are listed on a domestic or foreign stock exchange. The Foundation Board of the PensFlex Collective Foundation has incorporated the corresponding regulations into the Art. 3.5 of the Organisational Rules or Art. 4 of the Rules on Investment. A list of the voting record of the PensFlex Collective Foundation in the year 2020 is shown below. Voting Report for PensFlex Sammelstiftung Kauffmannweg 16 6003 Luzern This report summarizes voting behaviour according to the following specifications: Time period: 01.01.2020 - 31.12.2020 Agenda items: Summary of all items on the agenda, i.e. not only the items requiring a vote according to Art. 22 para. 1 ORAb. The voting rights were exercised for the following companies: Perrot Duval 06.02.2020 Kardex 14.04.2020 Novartis 28.02.2020 Tornos 15.04.2020 Dätwyler 11.03.2020 Georg Fischer 15.04.2020 Roche 17.03.2020 Sulzer 15.04.2020 BB Biotech 19.03.2020 Evolva 15.04.2020 Schindler 19.03.2020 Mikron 15.04.2020 Swiss Prime Site 24.03.2020 Ascom 15.04.2020 Implenia 24.03.2020 Kudelski 15.04.2020 Bellevue 24.03.2020 Adecco 16.04.2020 SGS 24.03.2020 Rieter 16.04.2020 ALSO 24.03.2020 Cembra Money Bank 16.04.2020 Givaudan 25.03.2020 Swiss Re 17.04.2020 Autoneum 25.03.2020 Siegfried 17.04.2020 ABB 26.03.2020 Calida 17.04.2020 Belimo 30.03.2020 Sika 21.04.2020 Mobimo 31.03.2020 Bachem 22.04.2020 Leonteq 31.03.2020 Vetropack 22.04.2020 SenioResidenz 01.04.2020 Santhera Pharmaceuticals 22.04.2020 Geberit 01.04.2020 Conzzeta 22.04.2020 Zurich Insurance Group 01.04.2020 SFS 23.04.2020 Huber+Suhner 01.04.2020 u-blox 23.04.2020 Coltene 02.04.2020 Nestlé 23.04.2020 Emmi 02.04.2020 Zur Rose 23.04.2020 Inficon 03.04.2020 Comet 23.04.2020 TX Group 03.04.2020 Bucher 24.04.2020 Forbo 03.04.2020 Bâloise 24.04.2020 Swisscom 06.04.2020 Allreal 24.04.2020 OC Oerlikon 07.04.2020 Metall Zug 24.04.2020 SIG Combibloc 07.04.2020 Helvetia 24.04.2020 Bobst 07.04.2020 Edisun 24.04.2020 Straumann 07.04.2020 Lindt & Sprüngli 24.04.2020 Zug Estates 07.04.2020 Arbonia 24.04.2020 VZ Holding 08.04.2020 Swiss Life 28.04.2020 Fundamenta Real Estate 08.04.2020 Lonza Group 28.04.2020 Bossard 08.04.2020 Investis 28.04.2020 mobilezone 08.04.2020 Molecular Partners 29.04.2020 Schweiter Technologies 08.04.2020 UBS 29.04.2020 Basilea 08.04.2020 EFG International 29.04.2020 Sunrise Communications 08.04.2020 Feintool 30.04.2020 Luzerner Kantonalbank 08.04.2020 Stadler Rail 30.04.2020 PSP Swiss Property 09.04.2020 Credit Suisse 30.04.2020 Plazza 09.04.2020 Banque Cantonale Vaudoise 30.04.2020 GAM 30.04.2020 HBM Healthcare Investments 22.06.2020 Zuger Kantonalbank 02.05.2020 Burkhalter 24.06.2020 Kühne + Nagel 05.05.2020 SenioResidenz 26.06.2020 Swissquote 05.05.2020 Clariant 29.06.2020 Pargesa 06.05.2020 Private Equity Holding 30.06.2020 Alcon 06.05.2020 Ypsomed 01.07.2020 Cham Group 06.05.2020 Burckhardt Compression 03.07.2020 Transocean 07.05.2020 Dottikon ES 03.07.2020 Komax 11.05.2020 Meyer Burger 10.07.2020 Sensirion 11.05.2020 EMS-Chemie 08.08.2020 Vaudoise Assurances 11.05.2020 Kühne + Nagel 02.09.2020 Bell 12.05.2020 Pargesa 04.09.2020 Berner Kantonalbank 12.05.2020 Logitech 09.09.2020 LafargeHolcim 12.05.2020 Richemont 09.09.2020 DKSH 13.05.2020 Aryzta 16.09.2020 Hypothekarbank Lenzburg 13.05.2020 Dufry 06.10.2020 Idorsia 13.05.2020 Peach Property Group 12.10.2020 nebag 13.05.2020 dormakaba 20.10.2020 Meyer Burger 13.05.2020 Züblin Immobilien 21.10.2020 Partners Group 13.05.2020 Sunrise Communications 09.11.2020 Swatch Group 14.05.2020 Richemont 17.11.2020 APG 14.05.2020 UBS 19.11.2020 SoftwareONE 14.05.2020 Dottikon ES 27.11.2020 VAT Group 14.05.2020 Credit Suisse 27.11.2020 Vifor Pharma 14.05.2020 EFG International 08.12.2020 BKW 15.05.2020 Barry Callebaut 09.12.2020 Jungfraubahn 18.05.2020 Aryzta 15.12.2020 Dufry 18.05.2020 Relief Therapeutics 17.12.2020 Tradition 19.05.2020 Galenica 19.05.2020 Valartis Group 19.05.2020 Romande Energie 19.05.2020 Orascom 20.05.2020 Temenos 20.05.2020 Alpine Select 20.05.2020 Spice Private Equity 27.05.2020 Peach Property Group 27.05.2020 Orior 04.06.2020 Valora 11.06.2020 Flughafen Zürich 11.06.2020 Sonova 11.06.2020 Züblin Immobilien 17.06.2020 Detailed overview Summary Approval of the management report and the annual and consolidated financial statements 2842 Agenda items 147 Agenda items thereof approval: 2294 thereof approval: 146 thereof rejection: 547 thereof rejection: 1 thereof abstention: 1 thereof abstention: 0 Dividend payment Payout from capital reserves 130 Agenda items 37 Agenda items thereof approval: 130 thereof approval: 37 thereof rejection: 0 thereof rejection: 0 thereof abstention: 0 thereof abstention: 0 Par value reduction Discharge BoD/BoM 9 Agenda items 111 Agenda items thereof approval: 8 thereof approval: 109 thereof rejection: 1 thereof rejection: 2 thereof abstention: 0 thereof abstention: 0 Discharge BoD Discharge BoM 34 Agenda items 5 Agenda items thereof approval: 34 thereof approval: 5 thereof rejection: 0 thereof rejection: 0 thereof abstention: 0 thereof abstention: 0 Consultative vote on compensation report Compensation vote BoD: fixed, prospective 97 Agenda items 131 Agenda items thereof approval: 48 thereof approval: 112 thereof rejection: 49 thereof rejection: 19 thereof abstention: 0 thereof abstention: 0 Compensation vote BoD: fixed, retrospective Compensation vote BoD: variable, prospective 7 Agenda items 6 Agenda items thereof approval: 5 thereof approval: 2 thereof rejection: 2 thereof rejection: 4 thereof abstention: 0 thereof abstention: 0 Compensation vote BoD: variable, retrospective Compensation vote BoM: fixed, prospective 7 Agenda items 56 Agenda items thereof approval: 0 thereof approval: 50 thereof rejection: 7 thereof rejection: 6 thereof abstention: 0 thereof abstention: 0 Compensation vote BoM: fixed, retrospective Compensation vote BoM: Variable, prospective 4 Agenda items 96 Agenda items thereof approval: 3 thereof approval: 63 thereof rejection: 1 thereof rejection: 33 thereof abstention: 0 thereof abstention: 0 Compensation vote BoM: Variable, Retrospective Re-election Chairman 47 Agenda items 118 Agenda items thereof approval: 32 thereof approval: 96 thereof rejection: 15 thereof rejection: 22 thereof abstention: 0 thereof abstention: 0 Election Chairman Election of new Board of Directors 17 Agenda items 131 Agenda items thereof approval: 17 thereof approval: 123 thereof rejection: 0 thereof rejection: 7 thereof abstention: 0 thereof abstention: 1 Re-election BoD Re-election Compensation Committee 819 Agenda items 346 Agenda items thereof approval: 699 thereof approval: 187 thereof rejection: 120 thereof rejection: 159 thereof abstention: 0 thereof abstention: 0 Election Compensation Committee Election Independent Proxy 75 Agenda items 138 Agenda items thereof approval: 67 thereof approval: 109 thereof rejection: 8 thereof rejection: 29 thereof abstention: 0 thereof abstention: 0 Election of auditor Ordinary capital increase 139 Agenda items 3 Agenda items thereof approval: 113 thereof approval: 3 thereof rejection: 26 thereof rejection: 0 thereof abstention: 0 thereof abstention: 0 Conditional capital: Extension Conditional capital: Creation 4 Agenda items 9 Agenda items thereof approval: 4 thereof approval: 3 thereof rejection: 0 thereof rejection: 6 thereof abstention: 0 thereof abstention: 0 Authorized capital: Extension Authorized capital: Creation 23 Agenda items 17 Agenda items thereof approval: 15 thereof approval: 9 thereof rejection: 8 thereof rejection: 8 thereof abstention: 0 thereof abstention: 0 Capital reduction Share buyback programme 15 Agenda items 2 Agenda items thereof approval: 12 thereof approval: 1 thereof rejection: 3 thereof rejection: 1 thereof abstention: 0 thereof abstention: 0 Amendments to the Articles of Incorporation Corporate Editorial revision of the Articles of Incorporation Governance 25 Agenda items 1 Agenda items thereof approval: 20 thereof approval: 1 thereof rejection: 5 thereof rejection: 0 thereof abstention: 0 thereof abstention: 0 Other amendments to the Articles of Incorporation M&A/restructuring 9 Agenda items 1 Agenda items thereof approval: 9 thereof approval: 1 thereof rejection: 0 thereof rejection: 0 thereof abstention: 0 thereof abstention: 0 Other topics Shareholder proposals: Election of the Board of Directors 6 Agenda items 6 Agenda items thereof approval: 5 thereof approval: 4 thereof rejection: 1 thereof rejection: 2 thereof abstention: 0 thereof abstention: 0 Amendments to the Articles of Incorporation ORAb 9 Agenda items 2 Agenda items thereof approval: 8 thereof approval: 1 thereof rejection: 1 thereof rejection: 1 thereof abstention: 0 thereof abstention: 0 No vote Compensation voting Advisory Board 7 Agenda items 3 Agenda items thereof approval: 4 thereof approval: 3 thereof rejection: 3 thereof rejection: 0 thereof abstention: 0 thereof abstention: 0.
Load more

Recommended publications
  • 2020 Annual Report HIGHLIGHTS SHAREHOLDER MANAGEMENT SUSTAINABILITY CORPORATE COMPENSATION FINANCIAL APPENDIX LETTER COMMENTARY REPORT GOVERNANCE REPORT REPORT 2
    2020 Annual Report HIGHLIGHTS SHAREHOLDER MANAGEMENT SUSTAINABILITY CORPORATE COMPENSATION FINANCIAL APPENDIX LETTER COMMENTARY REPORT GOVERNANCE REPORT REPORT 2 CONTENTS #TogetherStrong Highlights 3 #TogetherStrong is a tag-name that covers #TogetherStrong aptly describes how we countless initiatives we took to address progressed through and emerged from this Letter to shareholders 7 pressing needs in the dental community extraordinary year. Management commentary 11 in 2020. Straumann Group in brief 12 Strategy in action 17 #TogetherStrong is forward-looking; it Products, solutions and services 21 It started with a website offering scientific expresses purpose, teamwork, courage, Innovation 26 and practical information to help Markets 29 determination, perseverance, moving Business performance (Group) 35 customers and staff through the corona forward and succeeding in turbulent Business performance (Regions) 38 virus crisis. Soon it became a holistic, Business performance (Financials) 44 surroundings – themes that are captured Share performance 46 omni-channel response including a in the pictures and contents of this report. Risk management 49 massive education platform. Sustainability report 57 The #TogetherStrong concept has Corporate governance 80 extended to thousands of activities Compensation report 107 and millions of communications. It demonstrates how the events of 2020 Financial report 123 fuelled our resourcefulness, innovation Appendix 184 and passion for creating opportunities. Global Reporting Initiative (GRI) 185 GRI content
    [Show full text]
  • Market Notice Date: 14 November 2019 Market Notice Number: 112/2019
    Market Notice Date: 14 November 2019 Market Notice Number: 112/2019 Equiduct Universe Change Please see today's changes below effective 18 November 2019: Trading Reporting MIC Settlement Trading Settlement Tick Size Change/ Security Name ISIN Home Market Symbol Country Currency Currency table Action ABB LTD ABBNz CH0012221716 XSWX EQTB CH CHF CHF ESMA_E Deletion ABB ABBs CH0012221716 XSTO EQTB SE SEK SEK ESMA_E Deletion ADECCO SA ADENz CH0012138605 XSWX EQTC CH CHF CHF ESMA_E Deletion AMS AG AMSz AT0000A18XM4 XSWX EQTC CH CHF CHF ESMA_E Deletion ARYZTA AG ARYNz CH0043238366 XSWX EQTB CH CHF CHF ESMA_E Deletion JULIUS BAER GRUPPE AG BAERz CH0102484968 XSWX EQTC CH CHF CHF ESMA_E Deletion BALOISE-HLDGS BALNz CH0012410517 XSWX EQTC CH CHF CHF ESMA_D Deletion BARRY CALLEBAUT AG BARNz CH0009002962 XSWX EQTC CH CHF CHF ESMA_D Deletion BB BIOTECH BBZAd CH0038389992 XETR EQTB DE EUR EUR ESMA_D Deletion BB BIOTECH BIONz CH0038389992 XSWX EQTB CH CHF CHF ESMA_D Deletion BASILEA PHARMACEUTICA AG BSLNz CH0011432447 XSWX EQTC CH CHF CHF ESMA_D Deletion BUCHER INDUSTRIES BUCNz CH0002432174 XSWX EQTC CH CHF CHF ESMA_D Deletion COMPAGNIE FINANCIERE RICHEMONT CFRz CH0210483332 XSWX EQTC CH CHF CHF ESMA_E Deletion CLARIANT CLNz CH0012142631 XSWX EQTC CH CHF CHF ESMA_E Deletion CEMBRA MONEY BANK AG CMBNz CH0225173167 XSWX EQTC CH CHF CHF ESMA_D Deletion CREDIT SUISSE GROUP AG CSGNz CH0012138530 XSWX EQTC CH CHF CHF ESMA_E Deletion DKSH HOLDING DKSHz CH0126673539 XSWX EQTC CH CHF CHF ESMA_D Deletion DORMA+KABA HOLDING AG DOKAz CH0011795959 XSWX EQTC CH CHF
    [Show full text]
  • Longer Term Investments Medical Devices
    Longer Term Investments Medical devices Chief Investment Office GWM | 11 April 2019 6:53 pm BST Lachlan Towart, Analyst; Stefan R Meyer, Analyst • The aging population and growth of the over-65 age group will create more opportunities for companies selling medical products and devices. • Other drivers of this industry include better penetration in emerging markets due to improved infrastructure, innovative new treatments, increased affordability due to rising per-capita GDP and a growing prevalence of "lifestyle diseases" such as obesity due to urbanization. • We identified five key markets for implantable or wearable devices, including consumer products such as hearing aids, dental implants and corrective lenses. We estimate their total market size at USD 114.8bn with a rate of potential growth in the mid-single digits. • The theme is relatively defensive and should appeal to quality- focused investors. We recommend exposure to it via a diversified portfolio of stocks across our preferred markets and segments. Medical devices can assist in the treatment of many conditions. Some reduce the risk of a treated condition worsening, perhaps as an alternative to drug therapy; others improve users' quality of life or functionality; and still others can solve problems untreatable with drugs. Devices like joint replacements effectively offer permanent long-term solutions (i.e. a cure). Medical devices are primarily used by the over-65 age group, whose growth will outpace the broader population's over the coming decades. Demand is also supported by the rise of "lifestyle diseases" like obesity, itself related to urbanization. The medical device industry has matured, but still represents a substantial opportunity, in our view.
    [Show full text]
  • Contract Specifications for Futures Contracts and Eurex14 Options Contracts at Eurex Deutschland and Stand March 2831, 2008 Eurex Zürich Seite 1
    Contract Specifications for Futures Contracts and Eurex14 Options Contracts at Eurex Deutschland and Stand March 2831, 2008 Eurex Zürich Seite 1 [....] Annex A in relation to subsection 1.6 of the contract specifications: Futures on Shares of Produkt- Group Cash Contract Minimum Currency ID ID** Market- Size Price ID** Change* Julius Bär Holding AG - N. BAEG CH01 XSWX 50 0.0010.01 CHF BB Biotech AG BIOF CH01 XSWX 50 0.0010.01 CHF Logitech International S.A. - N. LOGF CH01 XSWX 100 0.00010.01 CHF Pargesa Holding S.A. PARF CH01 XSWX 10 0.0010.01 CHF Sonova Holding AG - N. PHBF CH01 XSWX 50 0.0010.01 CHF PSP Swiss Property AG - N. PSPF CH01 XSWX 50 0.0010.01 CHF Schindler Holding AG SINF CH01 XSWX 50 0.0010.01 CHF Straumann Holding AG STMF CH01 XSWX 10 0.0010.01 CHF Swatch Group AG, The - N. UHRF CH01 XSWX 100 0.00010.01 CHF Valiant Holding AG - N. VATF CH01 XSWX 10 0.0010.01 CHF ABB Ltd. ABBF CH02 XVTX 100 0.00010.01 CHF Adecco S.A. - N. ADEF CH02 XVTX 100 0.0010.01 CHF Actelion Ltd. - N. ATLG CH02 XVTX 50 0.0010.01 CHF Bâloise Holding AG BALF CH02 XVTX 100 0.0010.01 CHF Compagnie Financière Richemont AG CFRH CH02 XVTX 100 0.0010.01 CHF Ciba Spezialitätenchemie Holding AG - N. CIBF CH02 XVTX 10 0.0010.01 CHF Clariant AG - N. CLNF CH02 XVTX 100 0.00010.01 CHF Credit Suisse Group - N. CSGG CH02 XVTX 100 0.00010.01 CHF Geberit AG - N.
    [Show full text]
  • Julius Baer Multicooperation Annual Report 2005 As at June 30, 2005 (Audited)
    Julius Baer Multicooperation Annual Report 2005 as at June 30, 2005 (audited) Subscriptions are only valid if made on the basis of the current Prospectus, the latest Annual Report and the latest Semi-Annual Report if published thereafter. The Articles of Association, the valid Prospectus and the Annual and Semi-Annual Reports may be obtained free of charge at the representative in Switzerland and the respective paying agent. Only the German version of the present Annual Report has been reviewed by the independent auditor. Consequently, the independent auditor's report only refers to the German version of the Report; other versions result from a conscientious translation made under the responsibility of the Board. In case of differences between the German version and the translation, the German version shall be the authentic text. AN INVESTMENT FUND DOMICILED IN LUXEMBOURG Representative in Switzerland: Julius Baer Investment Funds Services Ltd., Zurich Paying agent in Switzerland: Bank Julius Bär & Co. AG, Bahnhofstrasse 36, Postfach, CH - 8010 Zurich Paying agent in Germany: Bank Julius Bär (Deutschland) AG, Messe Turm, Friedrich-Ebert-Anlage 49, Postfach 15 01 52, D - 60061 Frankfurt on the Main Paying agent in Austria: Erste Bank der oesterreichischen Sparkassen AG, Graben 21, A - 1010 Vienna Contents Page Organisation and Management 4 Independent Auditor's Report 5 Notes to the Financial Statements 6 Julius Baer Multicooperation (Umbrella Fund) MCOO Julius Baer Multicooperation - Emerging Markets Value Stock Fund HESF Julius Baer Multicooperation
    [Show full text]
  • First-Quarter 2021 Report – Media Release
    First-quarter 2021 report – Media Release Straumann Group reports very strong first-quarter sales results accelerated by product launches and consumer focus on oral health . Record quarterly revenue of CHF 470 million, 34% organic growth compared to previous year which was already impacted by the pandemic . Acquisition effect of 2% due to DrSmile . Recent investments and product launches driving growth, performance lifted by strong consumer focus on oral health . Strong organic double-digit growth in all regions; contributions led by the largest regions EMEA and North America . Investment of CHF 170 million by 2029 in China Campus to support future growth . Full-year 2021 outlook raised to organic revenue growth in the mid-to-high twenties percentage range expecting an improvement in profitability (core EBIT margin) compared to 2020 REVENUE BY REGION Q1 2021 Q1 2020 (in CHF million) Europe, Middle East & Africa (EMEA) 214.3 162.2 Change in CHF in % +32.1 0.9 Change in local currencies in % +33.1 7.5 Change organic1 in % +27.0 0.1 % of Group total 45.6 45.4 North America (NAM) 138.0 115.7 Change in CHF in % +19.4 4.9 Change in local currencies in % +27.0 7.9 Change organic1 in % +27.0 7.7 % of Group total 29.4 32.4 Asia Pacific 92.3 53.5 Change in CHF in % +72.4 -25.5 Change in local currencies in % +74.4 -21.7 Change organic1 in % +74.4 -22.1 % of Group total 19.6 15.0 Latin America 25.2 26.0 Change in CHF in % -3.1 -12.0 Change in local currencies in % +23.8 7.3 Change organic1 in % +23.8 7.2 % of Group total 5.4 7.3 GROUP 469.8 357.3 Change in CHF in % +31.5 -4.0 Change in local currencies in % +37.0 1.9 Change organic1 in % +34.0 -1.4 1 Excluding the effects of currencies and acquisitions Page 1/6 Basel, April 29, 2021: The Straumann Group made an exceptional start to 2021 and the solid growth trend experienced in the second half of 2020 accelerated.
    [Show full text]
  • Ntqlrethih1it6katsuy79yjfy6.Pdf
    Global Research 16 March 2021 Aryzta AG Equities Improved business model set up - upgrade to Buy Switzerland Food Products 12-month rating Buy * Upgrade to Buy after key corporate actions Prior: Neutral Aryzta has gone through challenging times but we believe new management actions 12m price target CHF1.50 unlock value prospects. We upgrade the stock to Buy from Neutral and raise our price Prior: CHF0.65 target to CHF1.5. In our view, the announced divestment of the underperforming Price (15 Mar 2021) CHF1.04 region North America with related proceeds (c€700m – transaction multiple c10.5x FY 20) used to de-lever the balance sheet is a game changer. Aryzta can now focus on the RIC: ARYN.S BBG: ARYN SW key value driver Europe. The improving balance sheet allows growth investments. With Trading data and key metrics c60% exposure to street traffic, we also think Aryzta should benefit from easing 52-wk range CHF1.04-0.29 COVID-19 mobility restrictions. We expect a strong net profit recovery to €81m by FY Market cap. CHF1.03bn/US$1.10bn 23E (FY 21E -€61m). The stock has EFCF run rate prospects of €70-100m medium term Shares o/s 990m (REG ) resulting in an attractive yield to market cap of 7-10% (Swiss mid cap food companies Free float 100% trade at 2-4%). Avg. daily volume ('000) 6,794 Restructuring on track and attractive exposure to consumer street traffic Avg. daily value (m) CHF5.4 To optimise the business model set up in Europe, Aryzta is de-layering management, Common s/h equity (07/21E) €0.19bn resulting in cost savings of c€20-30m (UBSe), but at the same time it is strengthening P/BV (07/21E) 4.9x local responsibility and client relations.
    [Show full text]
  • Straumann Group 2020 Full-Year Results
    #TogetherStrong Virtual2020 full-year townhall results meeting conference Basel, 16 February 2021 1 Disclaimer This presentation contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Straumann Group to differ materially from those expressed or implied in this presentation. The Group is providing the information in this presentation as of this date and does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise. The availability and indications/claims of the products illustrated and mentioned in this presentation may vary according to country. 2 2 FY 2020, Straumann Group 1 2/15/2021 9:46 PM Agenda Full-year highlights Guillaume Daniellot Business & regional review Peter Hackel Recent achievements & strategy in action Guillaume Daniellot Outlook 2021 Guillaume Daniellot Guillaume Daniellot Q&A and upcoming events Peter Hackel 3 Full-year highlights Guillaume Daniellot, CEO 4 FY 2020, Straumann Group 2 A challenging year with solid results returning to organic growth in the second half of 2020 REVENUE ORGANIC GROWTH1 CORE EBIT MARGIN2 CHF 1.4bn -6% 23.4% -11% vs 2019 +8% organic growth1 in Q4 IFRS EBIT margin: 11% CUSTOMER FOCUS EXPANSION OUTLOOK3 Immediacy DrSmile Further share gains Straumann BLX, Zygoma, TLX Entering into Direct-to-Consumer 2021: high-single-digit percentage marketing with doctor-led treatment organic revenue growth, core EBIT expected to improve vs 2020 1 Organic growth = excluding effects of currencies and business combinations 2 Core figures exclude one-time M&A effects, exceptional 5 pension-plan items, restructuring and non-recurring litigation expenses, amortization and impairment of goodwill and acquisition related intangible assets.
    [Show full text]
  • Switzerland Fund A-CHF for Investment Professionals Only FIDELITY FUNDS MONTHLY PROFESSIONAL FACTSHEET SWITZERLAND FUND A-CHF 31 AUGUST 2021
    pro.en.xx.20210831.LU0054754816.pdf Switzerland Fund A-CHF For Investment Professionals Only FIDELITY FUNDS MONTHLY PROFESSIONAL FACTSHEET SWITZERLAND FUND A-CHF 31 AUGUST 2021 Strategy Fund Facts The Portfolio Managers are bottom-up investors who believe share prices are Launch date: 13.02.95 correlated to earnings, and that strong earners will therefore outperform. They look to Portfolio manager: Andrea Fornoni, Alberto Chiandetti invest in companies where the market underestimates earnings because their Appointed to fund: 01.03.18, 01.08.11 sustainability is not fully appreciated. They also look for situations where the impact Years at Fidelity: 7, 15 company changes will have on earnings has not been fully recognised by the market. Fund size: CHF366m They aim to achieve a balance of different types of companies, so they can deliver Number of positions in fund*: 36 performance without adding undue risk. Fund reference currency: Swiss Franc (CHF) Fund domicile: Luxembourg Fund legal structure: SICAV Management company: FIL Investment Management (Luxembourg) S.A. Capital guarantee: No Portfolio Turnover Cost (PTC): 0.01% Portfolio Turnover Rate (PTR): 28.92% *A definition of positions can be found on page 3 of this factsheet in the section titled “How data is calculated and presented.” Objectives & Investment Policy Share Class Facts • The fund aims to provide long-term capital growth with the level of income expected Other share classes may be available. Please refer to the prospectus for more details. to be low. • The fund will invest at least 70% in Swiss company shares. Launch date: 13.02.95 • The fund has the freedom to invest outside its principal geographies, market sectors, industries or asset classes.
    [Show full text]
  • Julius Baer Multistock Société D'investissement À Capital Variable
    Julius Baer Multistock Société d'Investissement à Capital Variable Annual Report as at 30 June 2011 (audited) Subscriptions are carried out solely on the basis of the current prospectus or the simplified prospectus, or the “key investor information”, as soon as it is available, in conjunction with the latest annual report and the latest semi-annual report if published thereafter. The articles of association, the valid prospectus and the simplified prospectus, the annual and semi-annual reports (or the “key investor information”, as soon as it is available), as well as the information based on the SFA guidelines on transparency with regard to management fees, may be obtained free of charge from the representative in Switzerland and/or from the respective paying agent. In case of differences between the German version and the translation, the German version shall be the authentic text. AN INVESTMENT FUND DOMICILED IN LUXEMBOURG Representative in Switzerland: Swiss & Global Asset Management AG, Hardstraße 201, CH - 8005 Zurich (new address from 19 September 2011) Paying agent in Switzerland: Bank Julius Bär & Co. AG, Bahnhofstraße 36, Postfach, CH - 8010 Zurich Paying and information agent in Germany (until 31 December 2010): Bank Julius Bär Europe AG, An der Welle 1, Postfach 15 02 52, D - 60062 Frankfurt am Main Paying agent in Germany (since 1 January 2011): Deka Bank Deutsche Girozentrale, Hahnstraße 55, D - 60528 Frankfurt am Main Information agent in Germany (since 1 January 2011): Swiss & Global Asset Management Kapital AG, Taunusanlage 15, D - 60325 Frankfurt am Main Paying agent in Austria: Erste Bank der oesterreichischen Sparkassen AG, Graben 21, A - 1010 Vienna Representative and paying agent in Liechtenstein: LGT Bank in Liechtenstein AG, Herrengasse 12, FL - 9490 Vaduz Trade and Companies Register number: R.C.S.
    [Show full text]
  • Keyinvest Return Monitor Systematically Selected UBS Barrier Reverse Convertibles
    Structured investment products for clients in Switzerland KeyInvest Return Monitor Systematically selected UBS Barrier Reverse Convertibles The Return Monitor provides an overview of UBS Barrier Reverse Convertibles (BRCs) offering attractive potential returns. All selected BRCs are listed on the SIX Structured Products Exchange and tradeable on each trading day under normal market conditions. In focus are products that have at least three months left until maturity and an intact barrier. The three categories examined are: Attractive sideways return, high barrier distance and underlyings with a Buy Rating by UBS Research. Further information can be found on: ubs.com/renditemonitor Attractive sideways return Barrier distance Coupon p.a. Underlying Ask Currency Expiry Valor Sideways return p.a. (worst performer) 5.50% Bayer / Novartis / Roche / Sanofi 74.30 CHF 14/08/2020 A 39945568 15.1% 30.6% 8.00% CENTRICA PLC / E.ON / Electricite de France 78.70 EUR 10/08/2020 A 42686847 18.7% 28.2% 9.00% Credit Suisse / Deutsche Bank 82.10 CHF 13/07/2020 A 42078534 15.8% 26.3% 9.75% Enel / Fiat Chrysler / UniCredit 85.20 EUR 29/06/2020 39167120 28.3% 23.9% 9.00% Hewlett-Packard / IBM 93.27 USD 06/07/2020 A 42271711 31.2% 15.1% High barrier distance Barrier distance Coupon p.a. Underlying Ask Currency Expiry Valor Sideways return p.a. (worst performer) 12.00% Alcoa Corporation / US STEEL CORP 96.32 USD 12/06/2020 A 44506090 47.5% 15.3% 7.75% Colgate-Palmolive / Estée Lauder / L'Oréal 98.55 USD 22/06/2020 A 41905920 43.9% 15.4% 10.00% Nike / Under Armour Inc.
    [Show full text]
  • Geneva, May 15, 2017 MSCI GLOBAL STANDARD INDEXES The
    Geneva, May 15, 2017 MSCI GLOBAL STANDARD INDEXES The following are changes in constituents for the MSCI Global Standard Indexes which will take place as of the close of May 31, 2017. SUMMARY PER COUNTRY and PER REGION: Nb of Nb of Securities Securities Region Country Added Deleted Asia Pacific AUSTRALIA 1 1 JAPAN 3 2 HONG KONG 0 1 MALAYSIA 0 2 TAIWAN 2 1 KOREA 3 0 INDIA 2 1 PAKISTAN 6 0 CHINA 5 3 Nb of Nb of Securities Securities Region Country Added Deleted Europe, Middle East and Africa UNITED ARAB EMIRATES1 0 SWITZERLAND 1 1 DENMARK 1 0 SPAIN 1 2 FRANCE 1 1 ITALY 1 0 UNITED KINGDOM 1 1 TURKEY 1 0 SOUTH AFRICA 0 1 RUSSIA 1 0 EGYPT 1 1 Nb of Nb of Securities Securities Region Country Added Deleted Americas USA 22 7 CANADA 1 1 BRAZIL 1 1 COLOMBIA 1 1 ASIA PACIFIC MSCI AUSTRALIA INDEX Additions Deletions BLUESCOPE STEEL VOCUS GROUP MSCI JAPAN INDEX Additions Deletions DISCO CORP HOKURIKU ELECTRIC POWER KYUSHU RAILWAY CO MITSUBISHI LOGISTICS TOSOH CORP MSCI HONG KONG INDEX Additions Deletions None CATHAY PACIFIC AIRWAYS MSCI MALAYSIA INDEX Additions Deletions Page 1 MSCI Global Standard Indexes - May 15, 2017 © MSCI 2017, All rights reserved None BERJAYA SPORTS TOTO LAFARGE MALAYSIA MSCI TAIWAN INDEX Additions Deletions GLOBALWAFERS CASETEK HOLDINGS TAIWAN HIGH SPEED RAIL MSCI KOREA INDEX Additions Deletions DOOSAN BOBCAT None MEDY-TOX PANOCEAN MSCI INDIA INDEX Additions Deletions INDIAN OIL CORP DIVI'S LABORATORIES RURAL ELECTRIFICATION CO MSCI PAKISTAN INDEX Additions Deletions ENGRO CORPORATION None HABIB BANK LUCKY CEMENT MCB BANK OIL
    [Show full text]